Form 4: Cytokinetics EVP Buys Stock, Sells Options

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and disposed of 3,500 stock options.

Summary

• Fady Ibraham Malik, Executive Vice President of Research & Development at Cytokinetics Inc., engaged in a stock transaction on July 7, 2026.
• Malik acquired 3,500 shares of common stock at a price of $7.80 per share.
• Following this acquisition, Malik beneficially owns 157,402 shares of common stock.
• Concurrently, Malik disposed of 3,500 stock options at a price of $86.62 per option.
• After the option disposal, Malik beneficially owns 153,902 shares of common stock.
• The transaction involving the stock options was made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the executive's stock purchase is a positive signal, the disposal of options, even under a 10b5-1 plan, tempers the overall sentiment.

Positives

• Acquisition of 3,500 shares of common stock by a key executive, indicating confidence in the company.
• The executive's stock option disposal was executed under a Rule 10b5-1(c) plan, suggesting pre-planned and potentially non-insider trading related activity.

Negatives

• Disposal of 3,500 stock options at a significantly higher price ($86.62) than the acquisition price of the common stock ($7.80), which could be interpreted as a profit-taking move.

Risks

• The disposal of stock options could be perceived negatively by the market if not adequately explained by the 10b5-1 plan context.
• While the 10b5-1 plan is mentioned, the significant difference in prices between the stock acquisition and option disposal might raise questions about the executive's valuation of the company's stock.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions by an executive.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of stock by an executive can be a positive signal, while the disposal of options, even under a 10b5-1 plan, is often scrutinized by investors.

Stakeholder Impact

• Shareholders may view the executive's stock purchase as a sign of confidence, potentially positively impacting sentiment.
• The disposal of stock options, despite being under a 10b5-1 plan, might lead some investors to question the executive's long-term outlook or to interpret it as profit-taking.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Executive Compensation, SEC Filing, Malik Fady Ibraham, Research & Development